Schreiner MediPharm Develops Freeze-Lock Cryo Label for Frozen Medications

Novel marking label remains adhered despite extreme, subzero temperatures.

This content was submitted directly to this website by the supplier.

Smp Freeze Lock Cryo Label 2

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has developed Freeze-Lock, a cryo label that permanently withstands the subzero storage and transport temperatures needed for many cell and gene therapy medications or clinical trials—including those for COVID-19 mRNA vaccines. The new solution comprises two interlocking label layers that ensure reliable adhesive strength and product information readability.

The Schreiner MediPharm Freeze-Lock label consists of two components: a bottom and top label. First, the bottom label layer with a specialty microfine surface texture is applied to the empty, non-refrigerated container at room temperature. Next, the container is filled with the active ingredient and immediately cooled down for storage at subzero temperatures utilizing dry ice (-108.4 °F) or liquid nitrogen (-320.8 °F).

To mark the frozen container, it is removed from cold storage. The Freeze-Lock’s top label layer is dispensed and firmly pressed against the bottom label. (If a layer of ice has formed, this ice does not need to be removed.) The deep freeze adhesive of the top label combines with the bottom label’s texture and freezes in a matter of seconds. The result is a permanent bond between the label construction and the container, which is then returned to storage and transported in frozen condition.

Due to the specialty two-component label design, as well as the materials and adhesives used, the Freeze-Lock cryo label reliably adheres to the frozen container, ensuring important product information is not lost.

Companies in this article
More in Supplier News